Media coverage about Sinovac Biotech (NASDAQ:SVA) has trended somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.827985659552 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, BidaskClub cut Sinovac Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th.
Sinovac Biotech (SVA) opened at $8.11 on Wednesday. Sinovac Biotech has a 52-week low of $4.60 and a 52-week high of $8.67. The company has a market capitalization of $464.14, a PE ratio of -810.19 and a beta of 0.18.
Sinovac Biotech (NASDAQ:SVA) last posted its earnings results on Wednesday, November 22nd. The biopharmaceutical company reported $0.08 EPS for the quarter. The business had revenue of $31.37 million for the quarter.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Sinovac Biotech (NASDAQ:SVA) Stock Price” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/sinovac-biotech-sva-earning-somewhat-positive-media-coverage-study-finds.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.